As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

Aneesh Phadnis Mumbai
As price pressure mounts, pharma companies tap analytics to cut costs

Pharmaceutical companies, on account of price pressures and an intense regulatory gaze, are investing in data analytics and digital tools to sharpen their marketing focus and improve compliance. 
The move comes in the backdrop of price competitiveness in key markets and regulatory actions leading to adverse audit observations and warning letters.
“Businesses that digitalise will have a huge competitive advantage over others. At Cipla we are leveraging new-age technologies to drive efficiencies,” said Kedar Upadhye, Cipla's global chief financial officer.

Also Read

From Celin to Septran, GSK Pharma sold 8-10 tail-end brands in FY19

Anti-infective medicine sales slowing down: Pharmaceutical industry

US antitrust probe singes India's pharmaceutical firms; Sun Pharma falls 9%

Drug major GSK sold off up to 10 tail-end brands in FY19 including Celin

Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright

Poor consumer confidence hits rural FMCG demand; sales growth drag

Reliance Industries to acquire 87.6% stake in Fynd for Rs 295 crore

Failure a tremendous experience, increases probability of success: Nilekani

Bankers worry DSP's legal action will delay rescue of DHFL: Reports

Bankrupt Jet Airways extends deadline for initial bids to August 10


  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 5Y
  • MAX

First Published: Aug 03 2019 | 9:04 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to